Vitagel

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vitagel

Vitagel: Defining the Topical Retinoid Agent

Property Description
Active ingredient Vitamin A (Retinol, Retinyl Palmitate)
Form Gel or Hydrogel
Pharmacological class Dermatological Agent / Epithelial Protectant
Route of administration Topical (Dermal or Ocular)
Origin Derived (Synthetic derivatives and naturally sourced vitamins)

Vitagel is a pharmaceutical preparation classified as a topical retinoid agent, which utilizes derivatives of Vitamin A as its core active ingredient. This classification reflects the role of Vitamin A and its esters, such as Retinol and Retinyl Palmitate, in regulating cellular function and differentiation. The preparation is specifically designed for Topical (Dermal or Ocular) administration, focusing its action directly on surface tissues, and is often positioned as an accessible Over-the-Counter (OTC) option within the broader retinoid category.

What is Vitagel Made Of? Composition and Form

The product is supplied in the physical form of a Gel or Hydrogel, a water-based dosage form that ensures effective delivery and is a key differentiating feature for users preferring non-occlusive formulations. The active ingredients include the primary Vitamin A compound, frequently stabilized as an ester, and combined with auxiliary vitamins like Tocopherol (Vitamin E) and L-Ascorbic Acid (Vitamin C), making it a combination product. Retinol belongs to the class of retinoids. The non-greasy Hydrogel Base is chosen to facilitate rapid absorption.

General Purpose: How Vitagel Supports Epithelial Health

The fundamental purpose of Vitagel is to provide structural support and aid in the healthy regeneration of epithelial tissues. Its mechanism centers on promoting cellular turnover acceleration, where the retinoid component influences the life cycle of cells, thereby encouraging the renewal of the protective tissue barrier. A typical, neutral use scenario involves its application for maintaining general skin vitality and addressing minor texture irregularities. The general benefit is the maintenance of robust tissue integrity, aiding in a smoother, more uniform surface appearance.

Regulatory References

  1. Vitamin A: MedlinePlus Medical Encyclopedia

What side effects are possible with Vitagel?

Possible Side Effects and Safety Information

The safety profile for Vitagel, a topical retinoid agent, is defined primarily by local cutaneous reactions documented in official regulatory sources. These effects relate to the application site and follow a specific time course during therapy.

Frequency-Classified Adverse Reactions

The most frequently classified reactions are categorized as Very Common or Common, affecting the Skin and Subcutaneous Tissue system:

  • Very Common (Affecting ge 1 in 10 individuals): Skin pain, skin exfoliation (peeling), dryness, and erythema (redness) at the application site.
  • Common (Affecting ge 1 in 100 individuals): Burning or stinging sensation, pruritus (itching), and dermatitis.

Time-Related Safety Patterns

The onset of these localized effects typically demonstrates a time-related pattern. Official labeling states that irritation and other reactions often peak during the initial two weeks of treatment and generally diminish thereafter with continued use. An apparent exacerbation of inflammatory lesions may also occur during the early phase of treatment.

Safety-Related Restrictions and Specific Populations

Certain constraints on use are documented in regulatory labeling to manage risk:

  • Photosensitivity: The agent can cause increased susceptibility to ultraviolet (UV) light. Unprotected exposure to sunlight or other UV sources must be avoided or minimized.
  • Pregnancy and Lactation: Due to the known risks associated with the retinoid drug class, use is generally not recommended or advised against during pregnancy, and caution is advised while breast-feeding.
  • Existing Skin Conditions: Use is contraindicated or cautioned against on compromised skin, such as areas affected by eczema or severe sunburn, due to the high potential for severe local irritation.

Overdose and Emergency Response

Overdose and When to Seek Help

The official safety information for this product, which is classified as a surgical hemostat/medical device, defines the most serious exposure risk not as a traditional dose-related overdose but as a critical application error.

Emergency Actions Required

The most severe consequence of application error—specifically, injection into blood vessels—is explicitly warned against in the official labeling. The contraindication states that such an event may result in extensive intravascular clotting and even death. If this product is ever applied incorrectly, particularly if there is a risk of it entering the bloodstream, immediate emergency medical attention is required.

Overdose-Related Risk Regulatory-Defined Outcome
Application Error (Intravascular Injection) Extensive Intravascular Clotting and Death
General Adverse Event "Overdose" is listed as a reported event in clinical trials, though specific symptoms are not detailed.

Overdose Profile Context

Because this product is not a systemically absorbed drug, the regulatory overdose profile is structured around the consequence of a catastrophic misuse. The official documentation emphasizes the potential for an immediate, life-threatening crisis—extensive clot formation—if the product is allowed to enter the vascular system. This scenario represents the highest severity outcome associated with this product and necessitates the most urgent medical response.

Therapeutic Uses of Vitagel

Uses and Benefits of Vitagel: What It Treats

Vitagel is commonly used in clinical settings to manage two critical aspects of injury and surgery: controlling localized bleeding and offering structural assistance to damaged tissue. As a clinical application, this product is used as additional support to manage hemostasis when conventional methods are ineffective or impractical.


Controlling Bleeding in Acute Scenarios

This product is applied to address symptom clusters that may become intense or disruptive, such as localized bleeding and oozing. Its main purpose is to help manage hemostasis at the application site. This stabilization supports the clinical environment and assists with maintaining functional stability at the site. This supportive management may help ease the overall symptom load related to active bleeding. This use is relevant in situations where symptoms of blood loss require immediate, localized assistance.

“This supportive management may help ease the overall symptom load related to active bleeding.”

Quick Fact: Support for Bleeding Symptoms


Supporting Tissue Stability and Natural Healing

Vitagel offers structural support for injured tissue, which assists in the body's natural process of repair and regeneration. It is relevant in conditions involving tissue damage or structural weakness, providing a protective layer that stabilizes the treatment area. This supportive therapeutic benefit may contribute to a more manageable experience during recovery by assisting with maintaining functional stability. By stabilizing the area, it supports the natural process of tissue healing. The product is applied in clinical settings that involve acute or unstable symptom patterns, such as those related to bleeding or tissue damage.

Eligibility and Restrictions for Use

The official eligibility criteria for Vitagel Surgical Hemostat are established by regulatory documents, defining who can and cannot use the product based on patient status and procedural context.


Eligibility Scope

Populations for whom use is contraindicated:

  • Individuals with known hypersensitivity to any component of Vitagel, including known allergies to materials of bovine origin.

Populations for whom use is not established:

  • Children and pregnant women. Safety and effectiveness have not been established in these populations.

Eligibility-related restrictions:

  • Procedural Exclusions: Use is contraindicated in neurosurgical and ophthalmic procedures. It must not be injected into blood vessels.
  • Condition Restrictions: The product should not be used in the presence of infection, for the primary treatment of coagulation disorders, or to control profuse arterial bleeding.
  • Conditional Use: Caution is required when applied in contaminated areas, and the material must not be left in the renal pelvis or ureters after urological procedures.

Eligibility Classification

The eligibility profile is defined by absolute contraindications (e.g., component allergy) and Use Not Established statements that restrict its application in vulnerable populations (children, pregnant women). These constraints ensure the product is limited to its approved context as an adjunct to hemostasis in specific surgical settings.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines documented interaction patterns for Vitagel (Topical Vitamin A derivatives), focusing strictly on information found in government regulatory labeling.


Documented Interaction Patterns

Interaction Type Interacting Substance/Class Regulatory Constraint
Systemic Exposure Risk Systemic Vitamin A Supplements Co-administration is strongly avoided due to the documented risk of hypervitaminosis A (additive systemic exposure).
Severe Systemic Risk Tetracycline-Class Antibiotics Combination is restricted due to the specific, documented risk of benign intracranial hypertension (pseudotumor cerebri).
Additive Local Risk Other Topical Retinoids or Photosensitizing Agents Use is restricted to avoid additive local irritation and heightened photosensitivity (increased risk of sunburn/irritation).
Local Irritation Risk Abrasive topical products, high alcohol content preparations Concomitant use is advised to be avoided due to the potential for compounded local skin irritation and drying.

Regulatory documentation defines this interaction profile by restricting substances that increase the total systemic burden of Vitamin A to potentially toxic levels and by prohibiting co-use with agents that intensify the known local effects of irritation and sensitization. Patients with hepatic impairment may be at an increased risk of altered Vitamin A metabolism and hepatotoxicity.

Mechanism of Action

Genomic Regulation and Cellular Differentiation

Vitagel's mechanism initiates at the molecular core of the epithelial cell. The active metabolite acts as an agonist for Retinoic Acid Receptors (RARs), which are ligand-activated transcription factors that bind to the cell's DNA. This binding alters gene expression, modulating the cell cycle to accelerate keratinocyte turnover and influence differentiation patterns. This genomic action results in the tissue remodeling that contributes to the structural organization of the epithelial barrier.

Kinetic Constraints and Antioxidant Synergy

The mechanism of action inherently involves a delayed onset because its effects are dependent on the slow processes of local enzymatic conversion of the pro-drug into Retinoic Acid and the subsequent protein synthesis driven by gene transcription. Complementing this primary action, the auxiliary ingredients, Vitamins C and E, function as antioxidants and radical scavengers. This synergy involves the stabilization of the retinoid and the mitigation of cellular damage from oxidative stress in the newly forming epithelial structures, modulating the cellular differentiation pathway.

Dosage and Administration Information

How to Use Vitagel Surgical Hemostat — Administration Overview

Vitagel is designated for topical application only, used in the surgical environment to assist with controlling localized bleeding. The preparation is not for injection into blood vessels.


Administration Scope and Preparation

Instruction Detail
Route of Administration Topical application to the surgical site.
Dosing Schedule Non-fixed; applied as needed to cover the area of bleeding.
Preparation Requirements Involves the mixing of the kit components with the patient's own autologous plasma using a dual syringe system.
Age-Group Rules Safety and effectiveness have not been established for use in pediatric patients or pregnant women.

Use Pattern and Procedural Structure

Vitagel is intended for single application during a surgical procedure and is classified as an as-needed/on-demand hemostatic adjunct. It is designed to be left in place (in situ) after bleeding is controlled, as its components are absorbable by the body over approximately 30 days.

The procedural sequence involves:

  • Preparing the solution by combining the autologous plasma with the kit components.
  • Applying the resultant gel matrix directly to the bleeding site in a surgical setting.
  • Removing any excess material by gentle irrigation of the site once hemostasis is confirmed.
  • Leaving the remaining effective portion of the gel in place.

This protocol establishes a topical application that defines the administration as a single, acute surgical intervention, separate from other forms of drug administration.

Recent Clinical Evidence

Research evidence / Overview of Studies for Vitagel

Evidence for Epithelial Renewal and Photodamaged Skin (Topical Retinoid Agent)

The evidence base for the topical Vitamin A derivative formulation includes randomized controlled trials (RCTs) and other clinical studies. These studies were used in research exploring how changes in skin texture and visual signs of aging evolved in observed populations, particularly adults with sun damage. Researchers typically compared the active gel against a non-active vehicle (a plain gel base) over periods of several weeks to a few months.

Studies explored outcomes related to physical discomfort and aesthetic changes, such as fine lines, skin roughness, and changes in pigmentation patterns. Findings describe patterns observed in the studies where the retinoid formulation was evaluated against the vehicle for outcomes related to fine lines, roughness, and pigmentation. Additionally, research examined biological markers, such as markers related to tissue structure in the skin, and monitored the measurement of these markers during the study period.

Follow-up durations were limited in many of these studies. Comparative evidence is lacking, meaning there are few head-to-head trials that rigorously evaluate this specific formulation against other retinoids. The results apply only to the populations studied and do not offer insight into individual outcomes.

Evidence for Adjunctive Hemostasis (Surgical Hemostat)

The research for the non-retinoid, collagen-based surgical hemostat formulation includes the Premarket Approval (PMA) clinical trials and other controlled studies required by regulatory bodies. This product was studied for use as a supportive measure to manage localized bleeding and oozing during specific surgical procedures when conventional methods were insufficient or impractical.

These studies focused on acute, measurable outcomes describing episodic or acute changes. The primary measure monitored was the Time to Hemostasis (TTH), which is the time required for bleeding to stop at the surgical site following application. Findings describe that the product was evaluated by measuring time to hemostasis in the observed patient groups. This research describes immediate outcomes observed during the operation itself.

Long-Term Studies and Durability of Reported Outcomes

Research exploring short-term symptom changes in the topical retinoid area has focused primarily on periods up to six months to one year. There is limited information for long-term outcomes, and the durability of any observed change is not fully established. It is not yet clear from the existing data what follow-up is necessary to study the evolution of outcomes over many years.

Frequently Asked Questions (FAQ)

Common questions about Vitagel (FAQ)


Q: How is Vitagel different from similar products like [Name of similar product]? (Non-comparative)

Official product information describes Vitagel as a combination topical retinoid agent supplied in a non-greasy hydrogel base. Its formulation also includes auxiliary Vitamins C and E, which are described as functioning as antioxidants to support the retinoid action.


Q: Does Vitagel address the root cause of the condition or just the symptoms?

Regulatory documents describing the mechanism of action state that the active ingredient influences cellular function at a molecular level. The mechanism is described as modulating gene expression to influence cell turnover and promote tissue remodeling, which is related to structural processes.


Q: How long does it typically take before I notice the effects of Vitagel?

According to the official product information, the mechanism of action involves a delayed onset of effects. This delay is described because the resulting changes depend on slow biological processes, specifically the local enzymatic conversion of the pro-drug and subsequent protein synthesis within the skin cells.


Q: Is it normal to feel a tingling sensation after applying Vitagel?

Official labeling documents a range of localized adverse reactions, including burning or stinging sensations, skin pain, and redness (erythema) at the application site. These effects are classified as common or very common. They are described as often peaking during the initial two weeks of use and are generally observed to diminish with continued use.


Q: Can pregnant or breastfeeding individuals use Vitagel?

Official regulatory constraints classify the use of the retinoid agent during pregnancy as generally not recommended or advised against. This restriction is noted due to the known risks associated with the retinoid drug class. Caution is also noted in the official documentation regarding the use of the product by individuals who are breastfeeding.


Q: Are there any specific foods or drinks to avoid while using Vitagel?

Official regulatory information restricts co-use with high alcohol content topical preparations due to the potential for compounded local irritation. Similarly, co-administration with systemic Vitamin A supplements is strongly restricted due to the documented risk of hypervitaminosis A (excess Vitamin A in the body).


Q: Can Vitagel be used with other skin products or creams?

Official regulatory information defines constraints that prohibit the co-use of Vitagel with certain other products. Use is restricted with other topical retinoids, photosensitizing agents, or abrasive topical products to avoid potential compounded local irritation or a heightened risk of photosensitivity.


Q: What happens in the body when Vitagel is working (simplified explanation)?

The primary function of the active retinoid component is described as influencing the life cycle of cells in the epithelial tissues. This action is noted in official sources as contributing to the acceleration of cellular turnover, which is linked to the structural integrity and renewal of these surface tissues.


Q: Is Vitagel appropriate for children?

Official regulatory documents clearly state that the safety and effectiveness of Vitagel have not been established for use in pediatric patients. This means that evidence is not available to support its use in this population.


Q: Are there any age restrictions for using Vitagel?

Safety and effectiveness have not been established for use in pediatric patients. Apart from this specific population, no specific upper age restrictions for adult use are documented in the contraindication section of the official product information.


Q: Are there any long-term safety concerns associated with Vitagel?

Studies exploring the outcomes of the retinoid agent have focused primarily on periods up to six months to one year. Official sources indicate that there is limited information available for long-term outcomes, meaning the durability of any observed changes over many years is not fully established in existing data.


Q: Is Vitagel considered a 'biologic' medicine?

Official regulatory documentation classifies the product based on its context. The topical formulation is classified as a pharmaceutical preparation and a topical retinoid agent. The surgical hemostat formulation is described as a collagen-based product, which is not typically defined as a biologic medicine.


Q: What information is available about Vitagel's safety profile in the elderly?

Official constraints define specific populations, like pediatric patients and pregnant women, where use is not established. However, no specific restrictions or contraindications are documented in the official labeling related to the safety profile or use in the general elderly population.


Q: Does using Vitagel affect my ability to drive or operate machinery?

The official regulatory documentation for the topical retinoid agent primarily lists local cutaneous reactions (skin reactions). It does not generally include warnings related to central nervous system effects or impaired operating ability.


Q: What kind of specialist typically recommends Vitagel?

The product is defined by its two primary uses described in official sources. The topical retinoid agent is generally classified as a dermatological agent, while the surgical hemostat formulation is described for use in a surgical setting.


Q: Is it true that Vitagel is a synthetic product?

The composition of Vitagel includes components with different origins. Official information describes the product as having an origin that includes both synthetic derivatives (the retinoid component) and naturally sourced vitamins (Vitamins C and E).


Q: What does 'limited evidence' mean when discussing the research for Vitagel?

When official documents use this term, it reflects the constraints of the available clinical studies. It means that the follow-up durations in many studies were limited, and the long-term durability of any observed changes is not fully established by the existing data.


Q: Can I apply Vitagel if I have a wound or broken skin?

Official labeling restricts the use of the product on compromised skin. Examples of compromised skin cited include areas affected by eczema or severe sunburn, due to the documented high potential for severe local irritation at the application site.

How should Vitagel be stored and disposed of?

How to Store and Dispose of Vitagel?

The storage and handling of Vitagel (Topical Retinoid Agent) must adhere strictly to official regulatory guidelines to preserve its stability.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Environmental Protect from light, moisture, and excessive heat. The product must not be frozen.
Container/Safety Keep the tube tightly closed and store the medicine in the original container. Keep it out of the sight and reach of children.

Disposal Instructions

Unused or expired Vitagel must be disposed of according to local regulatory requirements, often through official drug take-back programs. The medicine must not be flushed down the toilet or disposed of in household wastewater to protect the environment. Follow the labeled instructions regarding product stability after the initial opening.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vitagel found in:

A-Z Index: